All species organize behaviors to optimally match daily changes in the environment, leading to pronounced activity/rest cycles that track the light/dark cycle. Endogenous, approximately 24-hour circadian rhythms in the brain, autonomic nervous system, heart, and vasculature prepare the cardiovascular system for optimal function during these anticipated behavioral cycles. Cardiovascular circadian rhythms, however, may be a double-edged sword. The normal amplified responses in the morning may aid the transition from sleep to activity, but such exaggerated responses are potentially perilous in individuals susceptible to adverse cardiovascular events. Indeed, the occurrence of stroke, myocardial infarction, and sudden cardiac death all have daily patterns, striking most frequently in the morning. Furthermore, chronic disruptions of the circadian clock, as with night-shift work, contribute to increased cardiovascular risk. Here we highlight the importance of the circadian system to normal cardiovascular function and to cardiovascular disease, and identify opportunities for optimizing timing of medications in cardiovascular disease.

Find the latest version:

http://jci.me/80590/pdf
Role of the circadian system in cardiovascular disease

Saurabh S. Thosar, Matthew P. Butler, and Steven A. Shea
Oregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, Oregon, USA.

All species organize behaviors to optimally match daily changes in the environment, leading to pronounced activity/rest cycles that track the light/dark cycle. Endogenous, approximately 24-hour circadian rhythms in the brain, autonomic nervous system, heart, and vasculature prepare the cardiovascular system for optimal function during these anticipated behavioral cycles. Cardiovascular circadian rhythms, however, may be a double-edged sword. The normal amplified responses in the morning may aid the transition from sleep to activity, but such exaggerated responses are potentially perilous in individuals susceptible to adverse cardiovascular events. Indeed, the occurrence of stroke, myocardial infarction, and sudden cardiac death all have daily patterns, striking most frequently in the morning. Furthermore, chronic disruptions of the circadian clock, as with night-shift work, contribute to increased cardiovascular risk. Here we highlight the importance of the circadian system to normal cardiovascular function and to cardiovascular disease, and identify opportunities for optimizing timing of medications in cardiovascular disease.

Introduction
Almost all cardiovascular (CV) variables that have been assessed at different times of day and night in humans have been found to have a day/night pattern, including blood pressure (BP) (1–3), heart rate (HR) (3), circulating catecholamines (4), blood coagulation markers (5), and vascular endothelial function (6). Moreover, epidemiological data reveal a robust morning increase in adverse CV events, including stroke (7, 8), myocardial infarction (9–11), serious ventricular arrhythmias (12), and sudden cardiac death (refs. 11, 13, and Figure 1). Typical morning behaviors (e.g., arousal from sleep, sudden change in posture after overnight recumbency, increased activity, and psychological stress) cause increases in sympathetic tone, vasoconstriction, peripheral arterial resistance, HR, BP, and platelet aggregability, and decreases in thrombolytic activity, parasympathetic tone, and vascular endothelial function (14). These daily CV fluctuations arise from the negative-feedback reactions to daily changes in the environment or behaviors that summate with anticipatory feed-forward effects on the CV system from the endogenous circadian system (Figure 2). Such CV changes in the morning may be advantageous in healthy individuals, but could be implicated in precipitating an adverse CV event in susceptible individuals (14–17).

Because of the Earth’s rotation, life on earth has evolved under conditions of predictable daily cycles of light and darkness. Organisms arrange their daily patterns of behaviors, such as the 24-hour fasting/feeding and rest/activity cycles, to optimally match these predictable changes in the environment. An endogenous circadian clock prepares the body for these anticipated daily cycles. For example, circulating cortisol and core body temperature increase during the last part of the night to prepare the metabolic and circulatory systems for abrupt increases in energy expenditure and activity soon after awakening (18). These anticipatory changes imply that physiological reactions are suboptimal without the circadian system appropriately priming or dampening responses based on time of day or night, perhaps because delays exist in some negative-feedback control systems (e.g., maximal release of cortisol after an acute stress can take up to 10 minutes; ref. 19).

We review the organization of the circadian system and discuss its role in the heart, vasculature, and blood; summarize circadian rhythms in resting CV physiology and especially the CV reactivity to stressors; and hypothesize how such circadian rhythms may relate to the established day/night pattern of adverse CV events (7, 9–13). We then examine how chronic disruptions of the internal clock, whether by night-shift work, airline jet lag, or social jet lag (20, 21), are deleterious to CV health. Finally, we highlight new research questions and consider the opportunities for optimizing timing of certain CV medications based on circadian rhythmicity of medication targets (chronotherapy).

Organization of the circadian system
Circadian timing of physiological function is widespread across the body. In humans and other mammals, the primary circadian pacemaker is the suprachiasmatic nucleus (SCN) of the hypothalamus. In rodents, lesions of the SCN abolish or attenuate daily rhythms in locomotor activity, body temperature, BP, and HR (22–24), showing that these rhythms are endogenous rather than resulting from daily changes in behavior or environment. SCN rhythms are primarily synchronized to the environment by light via the retinohypothalamic tract (25). The SCN is an autonomous oscillator and cycles even in vitro almost indefinitely (26). Moreover, dissociated SCN cells also remain rhythmic in culture, showing that rhythmicity is a cellular property (27). The SCN is critically important in coordinating molecular rhythms in all organs and cells across the body. In all nucleated cells, four families of core clock genes (Clock, Bmal1, Period [Per], and Cryptochrome [Cry]) form a transcription-translation feedback loop that cycles every approximately 24 hours (reviewed in refs. 28–35). CLOCK and BMAL1 act as positive regulators, dimerizing and initiating transcription of the Per and Cry genes. Translated PER and CRY proteins are negative elements in
and molecular signaling pathways (57, 58). Combined transcriptomic and metabolic data suggest that each day the cardiomyocyte cycles sequentially through an ATP generation phase to promote contractile function during the active period, then a nutrient storage phase towards the end of the active period, followed by a growth/repair phase in the rest/sleep period (59, 60).

Disruptions of the molecular clock in animals cause significant CV disease (61), exemplifying the importance of these rhythms. For instance, Bmal1 knockout in mice causes dilated cardiomyopathy (62) and selective Bmal1 knockout in cardiomyocytes eliminates much of the rhythmic transcriptome (63), reduces stroke volume and ejection fraction, and causes heart failure and early mortality in mice (63, 64). BMAL1 is a transcription factor with many genome-binding sites, so some of these results may be due to noncircadian BMAL1 roles, such as abnormal cardiomyocyte metabolism (63, 64). In mice, the circadian clock also controls ionic balance in the heart in a healthy range by regulating rhythms in Kruppel-like factor 15 and thereby kChIP2 (a voltage-gated potassium channel), with either deficiency or excess increasing susceptibility to serious ventricular arrhythmias (65). Cardiomyocyte-specific deletion of Bmal1 results in loss of normal circadian expression of the Na⁺ and K⁺ channels resulting in decreased HR and increased risk of arrhythmias (66), which could contribute to sudden cardiac death (67).

Blood vessels also exhibit circadian rhythmicity. For example, approximately 5% of all genes in the aorta are rhythmic (68). The vascular endothelium and vascular smooth muscle cells are important in regulating vascular resistance and BP. In animals, genes involved in structural integrity of vascular smooth muscle cells exhibit circadian rhythms (69). Functionally, targeted deletion of Bmal1 in murine vascular smooth muscle cells blunts the circadian amplitudes and advances the circadian phases of systolic and diastolic BP, and abolishes the circadian variation of pulse pressure (70).

The kidney is essential to long-term regulation of BP and approximately 13% of protein-coding genes in the kidney are rhythmic (41). PER1 plays an important role in BP maintenance by regulating aldosterone levels and affecting sodium retention (71–73). Bmal1-null mice exhibit lower BP with no circadian variation (74) perhaps in part because of the arrhythmicity in behaviors, including locomotor activity, in mice (75, 76). Patients with chronic kidney disease commonly lack the normal greater than 10% dip in nighttime BP compared with daytime BP. This so-called “non-dipping BP profile” (77, 78), which is associated with increased risk of adverse CV events and death in people with hypertension (79, 80). The precise role of the circadian system in nondipping hypertension is yet to be elucidated.

Tissue-specific circadian clocks across the CV system

In the heart, approximately 13% of genes and approximately 8% of proteins are rhythmic (53–56), particularly in growth, metabolism,
CV physiology, two classic protocols have been used that experimentally dissociate circadian clock effects from rhythmic behavioral and environmental effects (81). The first is the constant routine (82), in which environmental, behavioral, and postural changes are minimized for at least 24 hours. In our hands, participants maintained wakefulness while lying in a semirecumbent posture and consuming identical isocaloric snacks every 2 hours while in dim light, constant temperature, and with an absence of external time cues (83–86). In the constant routine, we observed clear circadian rhythms in many variables (83–86), but there are also potential changes caused by accumulating sleep loss (87, 88).

These two effects may be mathematically separated based on assumptions of an underlying 24-hour circadian sinusoidal rhythmicity that is superimposed on a monotonic effect of accumulating sleep loss (84). The second protocol is the forced desynchronization; it is implemented across multiple days and avoids the problem of accumulating sleep loss (Figure 3). Participants live on non-24-hour cycles of sleep and wakefulness with periods sufficiently far from 24 hours that their internal clocks cannot synchronize to the imposed artificial day length. We have used imposed behavioral cycles of 5 hours 20 minutes (89), 20 hours (90, 91), and 28 hours (92). The behaviors (sleep/wake, fasting/feeding, and inactivity/activity) therefore become desynchronized from the normal 24-hour schedule and thereby desynchronized from the endogenous circadian clock (Figure 3). By standardizing and balancing all behaviors evenly across the whole circadian cycle, a forced desynchronization protocol permits statistical determination of (a) an average circadian rhythm while controlling for all behavior effects (by aligning data according to the period of the circadian pacemaker at approximately 24 hours); (b) an average effect of a standardized behavior while controlling for any underlying circadian effects (by aligning data according to the period of the imposed artificial day length); and (c) any interaction between these effects, effectively determining if the responses to a behavior are different at different times of the body clock cycle (90, 91). In humans, food timing in these protocols does not appear to affect central circadian rhythms (18), but the effects on peripheral oscillators, for instance in adipose tissue or the liver, are unknown. In animals, timed feeding is a strong resetting cue for peripheral clocks (51, 52). To date, there have been far fewer investigations in humans, and any resetting effects of meals appear much smaller (93).

Circadian rhythm in hemodynamic regulation. Systemic BP is a ubiquitous measure in the clinic but is far from static across the day and night, and this day/night pattern of BP has clear clinical relevance. BP is usually lower in sleep than in wakefulness and has a characteristic surge after awakening, drawing parallels with the daily pattern of adverse CV events (refs. 94–97 and Figure 1). Indeed, in elderly patients with hypertension, a 10-mmHg systolic BP surge within 2 hours after waking is associated with a 22% greater risk of stroke, independent of the 24-hour average BP (98). The morning BP surge is not the only risk, as high nighttime BP (lack of nocturnal BP dipping) is a sensitive indicator for CV mortality, with 21% greater risk for each 10-mmHg increase in nighttime systolic BP and 9% greater risk for each 5-mmHg increase in nighttime diastolic BP (99).

Very few studies have measured the relative contributions of the daily pattern of behaviors and of the circadian clock to this day/night pattern of BP in humans. Two early studies that used 24-hour or 26-hour modified constant routine protocols reported no circadian rhythmicity of BP (100, 101). However, those studies had limitations, including exposure to light (which could affect circadian phase, ref. 102; suppress melatonin, ref. 103; and reduce potential melatonin-mediated dips in BP, ref. 104), lack of strict control of physical activity (which could introduce variable effects on BP), and lack of a circadian phase marker. In contrast, using three stringently controlled constant routine and forced desynchronization protocols that overcame these limitations, robust endogenous circadian rhythms in BP were discovered (83, 90). The endogenous circadian resting BP rhythm has an evening peak and a morning trough. Theoretically, the morning circadian trough could be protective by partially counteracting the BP surge related to arousal from sleep, sudden change in posture on awakening, and transient increase in

Figure 2. Conceptual model showing interactions between behavioral stressors, circadian timing, and individual susceptibility to cardiovascular risk. There is a constant interaction between behavioral stressors (e.g., exercise, circadian phases, and underlying individual risk. This results in resting physiological rhythms (e.g., blood pressure) and reactivity of those rhythms in the presence of stressors. In a healthy individual, the resting physiological rhythms are within normal limits and the reactivity to a stressor (upward-pointing arrows) is modest, such that the theoretical risk threshold for an adverse cardiovascular event is not crossed. However, in an individual susceptible to cardiovascular risk due to existing anatomic or physiological maladaptation, resting physiological rhythms may be elevated. Furthermore, in the presence of a stressor, the reactivity of physiological rhythms may be exaggerated and can cross the theoretical risk threshold for an adverse cardiovascular event such as stroke.
physical activity that occur around that time. The amplitudes of basal resting rhythms are small in healthy people (group average 3- to 6-mmHg peak-to-trough amplitudes) but may have clinical relevance, as they doubled upon exercise (90).

Regulators of BP, such as plasma epinephrine, norepinephrine, cortisol, cardiac vagal tone, and HR also exhibit circadian rhythms. Burgess et al. (105) compared autonomic nervous system function in participants who slept at night or were kept awake, reporting that rhythms in cardiac vagal tone were attributable to the circadian clock, but that rhythms in sympathetic tone depended on sleep. Nevertheless, light exposure during sleep deprivation was not controlled, which could have caused sympathetic activation and blunted any circadian rhythmicity. In contrast, more recent constant routine and forced desynchrony studies performed in constant dim light found different results (90, 106, 107). Sympathetic tone (circulating epinephrine and norepinephrine) had large endogenous circadian rhythms (peak-to-trough amplitudes of 70% and 34% of the mean, respectively) that peaked at a circadian phase equivalent to midday. The large time lag between the circadian peaks in sympathetic nervous system activity and BP (90) suggest that BP’s circadian rhythm is not driven by the sympathetic nervous system. Similarly, cortisol had a large circadian peak around the time of awakening, an effect that would likely counteract rather than contribute to the circadian rhythm of systolic BP (90). On the other hand, the efferent cardiac vagal tone (estimated from HR variability) had a circadian peak at approximately 8 am, coincident with the circadian basal BP trough (90), suggesting that circadian rhythms of BP and parasympathetic nervous system activity may be mechanistically related in resting healthy individuals.

In health, heartbeat dynamics exhibit complex fluctuations characterized by robust self-similar temporal structures, i.e., fractal regulation (108). A study using a forced desynchrony discovered that these temporal correlations have a circadian rhythm (independent from scheduled behaviors, activity, and mean HR) with signs of breaking down towards patterns seen in congestive heart failure during the vulnerable morning period (108). This raises the possibility that circadian-mediated influences on cardiac dynamics are involved in the day/night pattern of adverse cardiac events (107).

**Circadian rhythm in hemostatic regulation.** The ability to clot blood can be life-saving after an injury, but thrombi within vessels can contribute to myocardial infarction, ischemic stroke, and sudden cardiac death. Fibrinolytic activity helps break down thrombi and maintain vessel patency. The dynamic balance of platelet activation and fibrinolysis across the day and night may be involved in the morning increased risk for occlusive thrombi. For instance, highest platelet aggregability and highest concentration of plasminogen activator inhibitor-1 (PAI-1) occur in the morning (109, 110). A forced desynchrony protocol revealed that PAI-1 is rhythmic and peaks in the biological morning, suggesting a role for the circadian clock in reducing fibrinolytic activity in the morning, especially since this circadian rhythm was approximately 8 times larger than changes in PAI-1 induced by behaviors such as mild exercise (111). Indeed, several basic studies have demonstrated that PAI-1 gene expression is under molecular clock control (112–114). There are also effects of the circadian system on platelet activation, with a morning peak in platelet surface-activated GPIIb-IIIa, the final part of the platelet aggregation pathway (115). Thus, the circadian system appears to prepare healthy humans for increased ability to clot blood and reduce the breakdown of clots in the morning, with obvious potential clinical relevance in susceptible individuals. We speculate that
evolution has led to increased ability to clot blood in anticipation of increased laceration risk after awakening and becoming active. Yet, in people with CV vulnerabilities, increased clotting in the morning could increase the risk for adverse CV events (111). Indeed, aspirin reduces the morning peak in myocardial infarction (116), suggesting that the prothrombotic milieu in the morning is partly responsible for increased CV risk during that period.

Day/night pattern of vascular endothelial function. The vascular endothelium exerts remarkable control over the CV system, performing anti-atherosclerotic functions and regulating vascular patency via secretion of nitric oxide (117–119). A dysfunctional vascular endothelium is prognostic of adverse CV events (120). In animal studies, deletion or mutation of the core clock gene Per2 impairs acetylcholine-induced endothelial relaxation (121), impairs endothelial proliferation, and promotes endothelial aging (122). In humans, vascular endothelial function is relatively impaired in the morning (6, 123–126), and therefore potentially implicated in the morning increase in adverse CV events (127). Interestingly, in people with severe heart failure, endothelial function is impaired at all times, with loss of daily variation in endothelial function (128). Jones et al. (129) found decreased endothelial function across naps in the afternoon and at night, suggesting that either sleep or the inactivity that accompanies sleep accounts for the documented morning impairment in endothelial function (6, 123–126), although endogenous circadian system effects have not yet been appropriately investigated in healthy people or those with CV disease.

Circadian rhythms in CV reactivity to behaviors. While there is clear evidence of basal circadian rhythms in the CV system, reactions to physiological stressors are more likely to reveal vulnerabilities. Thus, interactions between the circadian system and the acute CV reactions to stressors may better exemplify the circadian system’s importance (Figure 2). Indeed, rather than a simple summation of circadian and behavioral effects, the same stressor may produce different CV responses at different circadian times (90, 91). Such nonlinear interactions presumably optimize function in healthy individuals but could theoretically set up the possibility of adverse CV events in susceptible individuals (Figures 1 and 2). For instance, ambulatory BP responses to acute increases in activity are higher in the morning (14), which may be optimal in physically active individuals but could trigger adverse CV events in habitually inactive individuals (130).

Since changes in posture and activity both usually occur during the vulnerable morning period following sleep, we determined whether CV responses to postural changes and exercise differ across the circadian cycle (90, 91). A 20-hour forced desynchrony in healthy individuals with tilt table tests (60° head-up for 15 minutes) across all phases of the circadian cycle revealed presyncope in 15% of all tests, with almost all cases (81%) occurring during the half of the circadian cycle corresponding to the biological night (2230–1030 hours) (91). Prior to that study, tilt table tests had rarely, if ever, been performed during the night, so this nocturnal period of increased vulnerability went unnoticed. This vulnerable period could have implications for individuals who become active during the night, such as shift workers, parents feeding their infants, and elderly people with increased nocturia and insomnia. In the identical 20-hour forced desynchrony it was found that the circadian system significantly modulated the vagal, sympathetic, and BP reactivity to mild cycle exercise (90). Notably, exercise-induced increases in epinephrine were twice as large in the morning (0830 hours) than in the middle of the night (0430 hours) (90). There were also significant circadian rhythms in the reactivity of parasympathetic markers, with the greatest cardiac vagal withdrawal during exercise across the morning period. These autonomic changes in the morning also corresponded to the circadian phase with the smallest systolic BP reactivity to cycle exercise (90). Rather than a simple 24-hour rhythm, the reactivities to exercise of both epinephrine and norepinephrine exhibited 12-hour rhythms with large peaks at circadian phases corresponding to 0700–1030 and 2000–2200 hours. Such 12-hour rhythms in reactivity to exercise could be related to 12-hour rhythms demonstrated in animal studies in, for instance, cardiac β-adrenergic receptor density and function (131), and gene transcription in liver, heart, kidney, and adrenals (132).

In summary, healthy people exhibit greatest sympathetic activation and greatest parasympathetic withdrawal during stresses in the biological morning, which corresponds to the time of the greatest risk of adverse events based on epidemiological data. Similar circadian CV studies are warranted in people with CV disease.

Night-shift work, circadian disruption, and social jet lag

Nowadays, the availability of artificial light at the flick of a switch provides the opportunity to adjust endogenous clock timing to a newly imposed light/dark cycle (e.g., night-shift work or jet lag) (25). However, repeated shifting of the endogenous circadian clock is injurious to health. Shift work is an independent risk factor for many chronic conditions, including heart disease (133–136), perhaps due to recurring disruptions of the circadian clock itself (e.g., light exposure at unusual circadian phases), or perhaps due to misalignment between the circadian clock and the behaviors (e.g., sleeping and fasting during the day, and being active and eating across the night). In humans, transient misalignment of behaviors and the circadian clock increases inflammation and impairs glucose regulation (137–140), with potential relevance to CV disease (141). A recent laboratory study of shift workers revealed that circadian misalignment increased 24-hour BP and CV inflammatory markers including IL-6, C-reactive protein, and TNF-α (142). Though similar measures after chronic circadian disruption are not available in humans, results in animal models suggest serious long-term consequences. Weekly 12-hour phase shifts of the light/dark cycle reduced longevity in cardiomyopathic hamsters by 11% (143). Cardiomyopathy was observed in hamsters whose internal circadian clock period did not match the external 24-hour light cycle (i.e., 20-hour period due to the tau mutation) (61, 144). Circadian disruption also slows recovery from CV events. For instance, recovery from experimentally induced myocardial ischemia is impaired in mice by rapidly shifting light/dark cycles, suggesting that sleep and circadian rhythm disruption that occurs in intensive care units may compromise recovery (145). Genetic manipulation of clock components impacts the ischemic tolerance of the heart, with some mutations worsening (146) and some improving the response (147). Thus, both external (light/dark cycle shifts) and internal (molecular clock disruption) impact CV health in mice.

Appropriately shifting circadian phase to match night-shift work is desirable but difficult and never immediate. Use of
bright light during night shifts and reducing light exposure following the end of night shifts (148–150) helps shift the circadian pacemaker and does improve performance, mood, and reduces sympathetic activity in night-shift workers who sleep during the daytime (151). However, in practice, daily light exposure, family and social demands, conflicting time cues on days off, and rapidly rotating shifts make appropriate circadian synchronization to the work schedule quite challenging (152). This means that work, meals, and sleep consistently occur at suboptimal circadian times. Clock-environment misalignment or clock-behavior misalignment are not limited to night-shift workers. A smaller but similar clock disruption is termed social jet lag, defined as the difference in the time of sleep between work/school days and free days (153). Approximately 70% of the population have noticeable social jet lag (i.e., their biological and social clocks differ by more than 1 hour) (154), and the greater the social jet lag, the greater the risk for obesity and diabetes (154–156). The effects of social jet lag on the CV system have not been well studied, though it is reported that greater social jet lag is associated with increased HR and higher cortisol levels (155). Moreover, a mere 1-hour advance in behaviors relative to circadian time, as occurs with a shift to daylight savings time in the spring, is associated with a transient increase in the incidence of myocardial infarctions (157). Applying circadian principles, such as appropriately timed light, darkness, and sleep, may help minimize circadian misalignment during night-shift work, but these circadian phase shifts are generally small and take numerous days to achieve such that some compromise seems inevitable (158). Thus, research on rapidly shifting the phase of the body clock to reduce misalignment is warranted. Indeed, the recent discovery that blockade of vasopressin receptors in the SCN accelerated recovery from jet lag in mice is promising in this regard (159).

Future research
The genes, receptors, cells, organs, and baseline physiology of the CV system all exhibit marked internal circadian rhythmicity. However, it is the interplay between these baseline circadian rhythms and the reactivity to daily changes in behavior or the environment that likely holds the key to answering whether and how circadian rhythms benefit the organism. It is also of interest to determine whether 24-hour circadian changes in CV variables follow the simple negative-feedback regulation principles that are well described for the CV system. For instance, acutely increased sympathetic activation invariably leads to increased HR; therefore, should we expect that a circadian peak in circulating catecholamines will cause a circadian peak in HR, or will a different dynamic relationship occur at these longer time scales? In animal models, it has been demonstrated that circadian rhythms in physiology are altered in disease states. Yet, modelling circadian disruption in humans is difficult, and most experiments have been performed on healthy participants. Therefore, a critical gap exists in the identification of the potential mechanisms by which the rhythms in CV physiology in healthy participants translate to people with existing CV disease. In particular, do normal physiological responses expose vulnerabilities at specific circadian phases in people made susceptible to adverse CV events because of underlying disease (Figure 2)? Moreover, it will be worthwhile to determine if CV circadian rhythms are affected by chronic CV disease. Another area for future exploration is to determine if the well-described racial disparities in CV risk (160) can be explained by potential racial differences in endogenous circadian rhythms (161).

Circadian clocks are very precise under constant conditions but can be reset using external stimuli. A promising area of clinical research is the use of small-molecule modifiers that target the circadian clock to reduce pathology, such as KLO01 for diabetes (162) and nobiletin for metabolic syndrome (163). In animal models, REV-ERBs has been shown to phase shift molecular clocks (164). A synthetic REV-ERB agonist taken by mice with diet-induced obesity reversed this obesity by reducing fat mass and improving dyslipidemia and hyperglycemia (165), while REV-ERBs upregulation increased muscle mitochondrial content and oxidative capacity (166). Conversely, in a clinical trial of timing of aortic valve replacement, perioperative myocardial injury was significantly lower in those undergoing surgery in the afternoon compared with the morning when myocardial REV-ERBα was highest (167).

Clinical directions: chronotherapy
The existence of clear epidemiological patterns of adverse CV events and the increase in CV risk in the face of abnormal diurnal patterns in physiology, such as the nondipping hypertension profile (77, 168), underline the importance of considering new time-based approaches to treat CV disease. A host of CV medications prescribed to help patients recover from and/or prevent heart disease include antithrombotics, β-adrenoceptor antagonists, calcium channel blockers, nitrates, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and cholesterol-lowering agents. Moreover, depending on specific CV diseases, their severity, and any comorbidities, most patients receive more than one medication (169). The goal of medication dosing is to optimize effectiveness without causing serious adverse side effects, both of which may depend on circadian time (170, 171). Furthermore, pharmacokinetics are driven by the absorption, distribution, metabolism, and excretion of a medication, each of which may be modulated by circadian rhythms (172). Indeed, gene expression is rhythmic for the targets of the majority of top-selling and essential medications listed by the World Health Organization (41), including angiotensin II receptor blockers, β-adrenoceptor antagonists, and aldosterone receptor blockers (41). Therefore, the field of chronotherapy—which considers the timing of medication doses relative to internal circadian phase, or more commonly the time of day—holds promise to improve care.

There are some classic examples where the time of CV medication administration resulted in differential effects on CV function (173). Use of β-adrenoceptor blockers reduces adverse CV events on an overall-population basis and abolishes the day/night pattern of such events (9, 174). It has been recommended to take extended-release β-adrenoceptor blockers in the evening, as this is sufficient to keep levels high during the morning vulnerable period (175). The morning surge of BP can be reduced in hypertensive patients by bedtime administration of a long-acting lipophilic ACE inhibitor (176). Likewise, low-dose aspirin can reduce the morning peak in myocardial infarction by approximately 60% (116), with evening aspirin theoretically being best to reduce potential for thrombus formation across the morning vulnerable period, although evidence from placebo-controlled
trials with long-term follow up of CV outcomes is lacking (177). Interestingly, in people with mild untreated hypertension, 100 mg aspirin at bedtime reduced 24-hour systolic BP by an average of 7 mmHg and diastolic BP by 5 mmHg, whereas a similar dose of aspirin upon awakening actually increased 24-hour systolic BP by an average of 3 mmHg and diastolic BP by 2 mmHg (178). Of note, mouse expression of cyclooxygenase-1 (COX-1), a target for aspirin, exhibits circadian rhythms in several tissues including the heart (41). Another study of the ACE inhibitor captopril showed that it reduced BP in mice at all times of day, but improved cardiac function only when administered at sleep time, potentially owing to captopril administration being in phase with increased ACE in the heart, and a consequent time-gated cardiac remodeling (179).

The MAPEC study of over 2,000 individuals with resistant hypertension is one of the few chronotherapeutic trials with long-term CV outcomes in humans (180). Patients in the MAPEC study were randomized to either change the timing of the dose of at least one antihypertensive medication to bedtime, or to maintain their usual practice of taking all hypertensive medications in the morning (180). Evening dosing reduced incidence of all CV events and CV mortality during 5.6 years of follow-up. These results were replicated in people with type II diabetes (181). While highly promising, the mechanisms are not yet understood, and double-blind placebo-controlled trials are now warranted with specific hypertensive medications rather than any hypertensive medication. In any chronotherapeutic trial, it should be noted that the magnitude of side effects can also depend on the time of dosing. For instance, a minor concern for evening chronotherapy using β-adrenoceptor blockers is that these medications can suppress normal melatonin release, which may affect sleep (182).

As the science of chronotherapeutics develops, we hope to move from simply prescribing medications relative to clock time (e.g., morning or evening with respect to our watches), or relative to daily behavioral patterns (e.g., before bedtime, or with a meal) to prescribing medications relative to endogenous biological time (i.e., circadian phases) and with possible consideration of any interaction between circadian phase and behavioral cycle on the effects of medications. These considerations can be important because internal circadian phase relative to external time or behavioral cycle varies between people, across ages, and depends on habitual light exposure (e.g., night-shift work). Moreover, if an evening dose is found effective, it will be important to determine if this is due to the circadian clock, for example via its regulation of a specific medication target that has circadian rhythmicity, or due to behaviors, such as meal history. Physicians may also wish to consider the possibility that comorbid conditions may affect the effectiveness of chronotherapy. For example, the vulnerable period for an adverse CV event in the general population is in the morning, coinciding with a morning surge in BP (183), but in patients with long-term (≥5 years) type I or II diabetes, the morning peak in myocardial infarction is significantly blunted (184). Similarly, the vulnerable period for sudden cardiac death is relatively advanced to the middle of the night rather than the morning in people with obstructive sleep apnea (185). Finally, we acknowledge that dosing according to internal circadian phase is presently somewhat impractical because estimation of internal phase (e.g., from serial salivary melatonin assays) is slow and expensive. Thus, development of an inexpensive, accurate, and instantaneous biomarker of internal circadian phase is a major challenge for the field.

Acknowledgments
The authors acknowledge funding from the National Space Biomedical Research Institute through NCC 9-58; NIH grants R01HL125893, R01HL140577, R01HL142064, R21HL140377, and F32HL131308; the Oregon Institute of Occupational Health Sciences; the Medical Research Foundation of Oregon; and the American Sleep Medicine Foundation.

Address correspondence to: Steven A. Shea, Oregon Health and Science University, Mail Code L606, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA. Phone: 503.494.2517; Email: sheast@ohsu.edu.


127. Ettsuda H, et al. Morning attenuation of endothe-

128. Buxton OM, Pavlova M, Reid EW, Wang W,

130. Willich SN, Lewis M, Löwel H, Arntz HR,

133. Knutsson A, Jonsson B, Akerstedt T, Orth-Gomer

138. Buxton OM, Pavlova M, Reid EW, Wang W,

142. Etsuda H, et al. Morning attenuation of endo-

143. Penev PD, Kolker DE, Zee PC, Turek FW. Chronic
circadian desynchronization decreases the surviv-

144. Hurd MW, Raphael MR. The significance of cir-

145. Alihaji FJ, et al. Short-term disruption of diurnal

146. Echle T, et al. Adorar2b-elicted Per2 stabilization

147. Durgan DJ, et al. Short communication: isch-

148. Boivin DB, Boudreau P, James FO, Kin NM. Phy-

149. Eastman CI, Stewart KT, Mahoney MP, Li L,

150. Crowley SJ, Lee C, Tseng CY, Fogg LF, Eastman

153. Wittmann M, Dinich J, Merrow M, Roenneberg T.


157. Jiddou MR, Pica M, Boura J, Qu L, Franklin BA.

159. Yamaguchi Y, et al. Mice genetically deficient in

160. Simonson DC, Adler GK. Sleep restriction for 1

162. Hirota T, et al. Identification of small mol-

163. He B, et al. The small molecule nobiletin targets

164. Meng QJ, et al. Ligand modulation of REV-

165. Soft LA, et al. Regulation of circadian behaviour

166. Wold E, et al. Rev-erbs-a modulates skeletal

167. Montaigne D, et al. Daytime variation of periop-

168. Birkenhager AM, van den Meiracker AH. Causes

169. Munger MA, Van Tassell BW, LaFleur J, Medi-

170. Pincus DJ, Szefler SJ, Ackerson LM, Martin RJ.

171. Levi F, Schibler U. Circadian rhythms: mecha-

172. Levi F, Schibler U. Circadian rhythms: mecha-

173. Litinski M, Scheer FA, Shea SA. Influence of the

174. Rosenthal KJ, Croft JB. State of disparities in cardio-

177. Bem D, et al. The effects of different aspirin

178. Chung BY, Liu JF, Chai YF, Wong FK, Zhao Y.

179. Sica D, Frishman WH, Manowitz N. Pharmacoki-


183. Martino TA, et al. The primary benefits of angio-

184. The Journal of Clinical Investigation

185. The Journal of Clinical Investigation

186. The Journal of Clinical Investigation

187. The Journal of Clinical Investigation

188. The Journal of Clinical Investigation

189. The Journal of Clinical Investigation

190. The Journal of Clinical Investigation

191. The Journal of Clinical Investigation

192. The Journal of Clinical Investigation

193. The Journal of Clinical Investigation

194. The Journal of Clinical Investigation

195. The Journal of Clinical Investigation

196. The Journal of Clinical Investigation

197. The Journal of Clinical Investigation

198. The Journal of Clinical Investigation

199. The Journal of Clinical Investigation

200. The Journal of Clinical Investigation

201. The Journal of Clinical Investigation

202. The Journal of Clinical Investigation

203. The Journal of Clinical Investigation

204. The Journal of Clinical Investigation

205. The Journal of Clinical Investigation

206. The Journal of Clinical Investigation

207. The Journal of Clinical Investigation

208. The Journal of Clinical Investigation

209. The Journal of Clinical Investigation

210. The Journal of Clinical Investigation

211. The Journal of Clinical Investigation

212. The Journal of Clinical Investigation

213. The Journal of Clinical Investigation

214. The Journal of Clinical Investigation

215. The Journal of Clinical Investigation

216. The Journal of Clinical Investigation

217. The Journal of Clinical Investigation

218. The Journal of Clinical Investigation

219. The Journal of Clinical Investigation

220. The Journal of Clinical Investigation

221. The Journal of Clinical Investigation

222. The Journal of Clinical Investigation

223. The Journal of Clinical Investigation

224. The Journal of Clinical Investigation

225. The Journal of Clinical Investigation

226. The Journal of Clinical Investigation

227. The Journal of Clinical Investigation

228. The Journal of Clinical Investigation

229. The Journal of Clinical Investigation

230. The Journal of Clinical Investigation

231. The Journal of Clinical Investigation

232. The Journal of Clinical Investigation

233. The Journal of Clinical Investigation

234. The Journal of Clinical Investigation

235. The Journal of Clinical Investigation

236. The Journal of Clinical Investigation

237. The Journal of Clinical Investigation

238. The Journal of Clinical Investigation

239. The Journal of Clinical Investigation

240. The Journal of Clinical Investigation

241. The Journal of Clinical Investigation

242. The Journal of Clinical Investigation

243. The Journal of Clinical Investigation

244. The Journal of Clinical Investigation

245. The Journal of Clinical Investigation

246. The Journal of Clinical Investigation

247. The Journal of Clinical Investigation

248. The Journal of Clinical Investigation

249. The Journal of Clinical Investigation

250. The Journal of Clinical Investigation

251. The Journal of Clinical Investigation

252. The Journal of Clinical Investigation

253. The Journal of Clinical Investigation

254. The Journal of Clinical Investigation

255. The Journal of Clinical Investigation

256. The Journal of Clinical Investigation

257. The Journal of Clinical Investigation

258. The Journal of Clinical Investigation

259. The Journal of Clinical Investigation

260. The Journal of Clinical Investigation

261. The Journal of Clinical Investigation

262. The Journal of Clinical Investigation

263. The Journal of Clinical Investigation

264. The Journal of Clinical Investigation

265. The Journal of Clinical Investigation

266. The Journal of Clinical Investigation

267. The Journal of Clinical Investigation

268. The Journal of Clinical Investigation

269. The Journal of Clinical Investigation

270. The Journal of Clinical Investigation

271. The Journal of Clinical Investigation

272. The Journal of Clinical Investigation

273. The Journal of Clinical Investigation

274. The Journal of Clinical Investigation

275. The Journal of Clinical Investigation

276. The Journal of Clinical Investigation

277. The Journal of Clinical Investigation

278. The Journal of Clinical Investigation

279. The Journal of Clinical Investigation

280. The Journal of Clinical Investigation

281. The Journal of Clinical Investigation

282. The Journal of Clinical Investigation

283. The Journal of Clinical Investigation

284. The Journal of Clinical Investigation

285. The Journal of Clinical Investigation

286. The Journal of Clinical Investigation

287. The Journal of Clinical Investigation

288. The Journal of Clinical Investigation

289. The Journal of Clinical Investigation

290. The Journal of Clinical Investigation

291. The Journal of Clinical Investigation

292. The Journal of Clinical Investigation

293. The Journal of Clinical Investigation

294. The Journal of Clinical Investigation

295. The Journal of Clinical Investigation

296. The Journal of Clinical Investigation

297. The Journal of Clinical Investigation

298. The Journal of Clinical Investigation

299. The Journal of Clinical Investigation

300. The Journal of Clinical Investigation

301. The Journal of Clinical Investigation

302. The Journal of Clinical Investigation

303. The Journal of Clinical Investigation

304. The Journal of Clinical Investigation

305. The Journal of Clinical Investigation

306. The Journal of Clinical Investigation

307. The Journal of Clinical Investigation

308. The Journal of Clinical Investigation

309. The Journal of Clinical Investigation

310. The Journal of Clinical Investigation

311. The Journal of Clinical Investigation

312. The Journal of Clinical Investigation

313. The Journal of Clinical Investigation

314. The Journal of Clinical Investigation